RNA interference-mediated targeting of human cytomegalovirus immediate-early or early gene products inhibits viral replication with differential effects on cellular functions

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5660-5673

  Xiaofei, E ^a   Stadler, Bradford M ^a   Debatis, Michelle ^a   Wang, Shixia ^a   Lu, Shan ^a   Kowalik, Timothy F ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROMYELOCYTIC LEUKEMIA PROTEIN; SMALL INTERFERING RNA; SMALL INTERFERING RNA X3; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOPATHOGENIC EFFECT; DNA DAMAGE; DNA REPLICATION; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; EXON; GENE PRODUCT; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA INTERFERENCE; RNA SEQUENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; VIRUS REPLICATION;

CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA DAMAGE; DNA-DIRECTED DNA POLYMERASE; DOWN-REGULATION; GENE EXPRESSION REGULATION, VIRAL; HUMANS; IMMEDIATE-EARLY PROTEINS; NUCLEAR PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; VIRAL PROTEINS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 5;

EID: 84861318527     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06338-11     Document Type: Article

References (86)

1. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. 1996. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40:2004-2011.
2. Aouadi M, et al. 2009. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458:1180-1184.
3. Bai Y, et al. 2011. Oral delivery of RNase P ribozymes by Salmonella inhibits viral infection in mice. Proc. Natl. Acad. Sci. U. S. A. 108:3222-3227.
4. Bai Z, et al. 2010. Inhibition of human cytomegalovirus infection by IE86-specific short hairpin RNA-mediated RNA interference. Biosci. Biotechnol. Biochem. 74:1368-1372.
5. Baldanti F, et al. 2004. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. J. Antimicrob. Chemother. 53:536-539.
6. Blaho JA. 2010. Human cytomegalovirus infection in pregnant women and neonates: a new risk factor for cardiovascular disease? Arch. Clin. Microbiol. 1:1-5.
7. Borden KL. 2002. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell. Biol. 22: 5259-5269.
8. Bradley SP, et al. 2005. Successful incorporation of short-interfering RNA into islet cells by in situ perfusion. Transplant. Proc. 37:233-236.
9. Butz K, et al. 2003. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22:5938-5945.
10. Casavant NC, et al. 2006. Potential role for p53 in the permissive life cycle of human cytomegalovirus. J. Virol. 80:8390-8401.
11. Castillo JP, et al. 2005. Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/p21-mediated growth arrest response. J. Virol. 79:11467-11475.
12. Castillo JP, Kowalik TF. 2002. Human cytomegalovirus immediate early proteins and cell growth control. Gene 290:19-34.
13. Castillo JP, Yurochko AD, Kowalik TF. 2000. Role of human cytomegalovirus immediate-early proteins in cell growth control. J. Virol. 74: 8028-8037.
14. Chan G, Hemmings DG, Yurochko AD, Guilbert LJ. 2002. Human cytomegalovirus-caused damage to placental trophoblasts mediated by immediate-early gene-induced tumor necrosis factor-alpha. Am. J. Pathol. 161:1371-1381.
15. Chang CP, Malone CL, Stinski MF. 1989. A human cytomegalovirus early gene has three inducible promoters that are regulated differentially at various times after infection. J. Virol. 63:281-290.
16. Chang L, et al. 2011. Herpesviral replication compartments move and coalesce at nuclear speckles to enhance export of viral late mRNA. Proc. Natl. Acad. Sci. U. S. A. 108:E136-E144.
17. Chiou SH, et al. 2006. The immediate early 2 protein of human cytomegalovirus (HCMV) mediates the apoptotic control in HCMV retinitis through up-regulation of the cellular FLICE-inhibitory protein expression. J. Immunol. 177:6199-6206.
18. Cobbs CS, et al. 2002. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62:3347-3350.
19. Cobbs CS, Soroceanu L, Denham S, Zhang W, Kraus MH. 2008. Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity. Cancer Res. 68:724-730.
20. Das AT, et al. 2004. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78:2601-2605.
21. Devi GR. 2006. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13:819-829.
22. Dittmer A, Bogner E. 2006. Specific short hairpin RNA-mediated inhibition of viral DNA packaging of human cytomegalovirus. FEBS Lett. 580:6132-6138.
23. Drew WL, et al. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716-719.
24. Duan QJ, Tao R, Hu MF, Shang SQ. 2009. Efficient inhibition of human cytomegalovirus UL122 gene expression in cell by small interfering RNAs. J. Basic Microbiol. 49:531-537.
25. Dziurzynski K, et al. 2011. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin. Cancer Res. 17:4642-4649.
26. E X, et al. 2011. An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus. PLoS Pathog. 7:e1001342.
27. Eckle T, et al. 2002. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant. 30: 433-439.
28. Erice A. 1999. Resistance of human cytomegalovirus to antiviral drugs. Clin. Microbiol. Rev. 12:286-297.
29. Erice A, et al. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N. Engl. J. Med. 320:289-293.
30. Fehr AR, Yu D. 2011. Human cytomegalovirus early protein pUL21a promotes efficient viral DNA synthesis and the late accumulation of immediate-early transcripts. J. Virol. 85:663-674.
31. Ge Q, et al. 2003. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. U. S. A. 100:2718-2723.
32. Gitlin L, Karelsky S, Andino R. 2002. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418:430-434.
33. Hagemeier C, Walker SM, Sissons PJ, Sinclair JH. 1992. The 72K IE1 and 80K IE2 proteins of human cytomegalovirus independently transactivate the c-fos, c-myc and hsp70 promoters via basal promoter elements. J. Gen. Virol. 73:2385-2393.
34. Hannon GJ. 2002. RNA interference. Nature 418:244-251.
35. Henderly DE, Freeman WR, Causey DM, Rao NA. 1987. Cytomegalovirus retinitis and response to therapy with ganciclovir. Ophthalmology 94:425-434.
36. Hermiston TW, Malone CL, Witte PR, Stinski MF. 1987. Identification and characterization of the human cytomegalovirus immediate-early region 2 gene that stimulates gene expression from an inducible promoter. J. Virol. 61:3214-3221.
37. Hwang ES, et al. 2009. Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J. Virol. 83:12388-12398.
38. Johnson RA, Yurochko AD, Poma EE, Zhu L, Huang ES. 1999. Domain mapping of the human cytomegalovirus IE1-72 and cellular p107 proteinprotein interaction and the possible functional consequences. J. Gen. Virol. 80:1293-1303.
39. Kapadia SB, Brideau-Andersen A, Chisari FV. 2003. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. U. S. A. 100:2014-2018.
40. Khanna R, Diamond DJ. 2006. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol. Med. 12:26-33.
41. Knox KK, Drobyski WR, Carrigan DR. 1991. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 337:1292-1293.
42. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408.
43. Lucas KG, Bao L, Bruggeman R, Dunham K, Specht C. 2011. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J. Neurooncol. 103:231-238.
44. Luo MH, Rosenke K, Czornak K, Fortunato EA. 2007. Human cytomegalovirus disrupts both ataxia telangiectasia mutated protein (ATM)-and ATM-Rad3-related kinase-mediated DNA damage responses during lytic infection. J. Virol. 81:1934-1950.
45. Malone CL, Vesole DH, Stinski MF. 1990. Transactivation of a human cytomegalovirus early promoter by gene products from the immediateearly gene IE2 and augmentation by IE1: mutational analysis of the viral proteins. J. Virol. 64:1498-1506.
46. Marchini A, Liu H, Zhu H. 2001. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. J. Virol. 75:1870-1878.
47. Mitchell DA, et al. 2008. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol. 10:10-18.
48. Mocarski E. 1996. Cytomegaloviruses and their replication, p 2447-2492. In Fields BN, et al (ed), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, PA.
49. Muganda P, Mendoza O, Hernandez J, Qian Q. 1994. Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts. J. Virol. 68:8028-8034.
50. Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM. 1998. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42:971-973.
51. Murphy EA, Streblow DN, Nelson JA, Stinski MF. 2000. The human cytomegalovirus IE86 protein can block cell cycle progression after inducing transition into the S phase of permissive cells. J. Virol. 74:7108-7118.
52. Nekhai S, Jerebtsova M. 2006. Therapies for HIV with RNAi. Curr. Opin. Mol. Ther. 8:52-61.
53. Netterwald J, et al. 2005. Two gamma interferon-activated site-like elements in the human cytomegalovirus major immediate-early promoter/ enhancer are important for viral replication. J. Virol. 79:5035-5046.
54. Nykanen A, Haley B, Zamore PD. 2001. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell 107: 309-321.
55. Palliser D, et al. 2006. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439:89-94.
56. Pass RF. 2001. Cytomegalovirus, p 2675-2706. In Knipe DM, et al (ed), Fields virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
57. Peggs KS. 2004. Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy. Expert Rev. Anti Infect. Ther. 2:559-573.
58. Pizzorno MC, O'Hare P, Sha L, LaFemina RL, Hayward GS. 1988. Trans-activation and autoregulation of gene expression by the immediateearly region 2 gene products of human cytomegalovirus. J. Virol. 62:1167-1179.
59. Polis MA. 1992. Foscarnet and ganciclovir in the treatment of cytomegalovirus retinitis. J. Acquir. Immune Defic. Syndr 5(Suppl. 1):S3-S10.
60. Puchtler E, Stamminger T. 1991. An inducible promoter mediates abundant expression from the immediate-early 2 gene region of human cytomegalovirus at late times after infection. J. Virol. 65:6301-6306.
61. Ranganathan P, Clark PA, Kuo JS, Salamat MS, Kalejta RF. 2012. Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J. Virol. 86:854-864.
62. Regad T, Chelbi-Alix MK. 2001. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20:7274-7286.
63. Sampson JH, Mitchell DA. 2011. Is cytomegalovirus a therapeutic target in glioblastoma? Clin. Cancer Res. 17:4619-4621.
64. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. 2008. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol. 116:79-86.
65. Schleiss MR. 2008. Congenital cytomegalovirus infection: update on management strategies. Curr. Treat. Options Neurol. 10:186-192.
66. Scholz M, Doerr HW, Cinatl J. 2001. Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option? Antiviral Res. 49: 129-145.
67. Shen YH, et al. 2004. Human cytomegalovirus causes endothelial injury through the ataxia telangiectasia mutant and p53 DNA damage signaling pathways. Circ. Res. 94:1310-1317.
68. Shin MC, et al. 2006. Inhibition of UL54 and UL97 genes of human cytomegalovirus by RNA interference. Acta Virol. 50:263-268.
69. Smuda C, Bogner E, Radsak K. 1997. The human cytomegalovirus glycoprotein B gene (ORF UL55) is expressed early in the infectious cycle. J. Gen. Virol. 78:1981-1992.
70. Speir E, et al. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394.
71. Stenberg RM, Depto AS, Fortney J, Nelson JA. 1989. Regulated expression of early and late RNAs and proteins from the human cytomegalovirus immediate-early gene region. J. Virol. 63:2699-2708.
72. Stenberg RM, Witte PR, Stinski MF. 1985. Multiple spliced and unspliced transcripts from human cytomegalovirus immediate-early region 2 and evidence for a common initiation site within immediate-early region 1. J. Virol. 56:665-675.
73. Straat K, et al. 2009. Activation of telomerase by human cytomegalovirus. J. Natl. Cancer Inst. 101:488-497.
74. Tao R, Hu M, Duan Q, Shang S. 2008. Efficient inhibition of human cytomegalovirus DNA polymerase expression by small hairpin RNA in vitro. Curr. Microbiol. 57:395-400.
75. Trang P, et al. 2000. Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 97:5812-5817.
76. Tsai HL, Kou GH, Chen SC, Wu CW, Lin YS. 1996. Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J. Biol. Chem. 271:3534-3540.
77. White EA, Clark CL, Sanchez V, Spector DH. 2004. Small internal deletions in the human cytomegalovirus IE2 gene result in nonviable recombinant viruses with differential defects in viral gene expression. J. Virol. 78:1817-1830.
78. White EA, Spector DH. 2005. Exon 3 of the human cytomegalovirus major immediate-early region is required for efficient viral gene expression and for cellular cyclin modulation. J. Virol. 79:7438-7452.
79. Wiebusch L, Truss M, Hagemeier C. 2004. Inhibition of human cytomegalovirus replication by small interfering RNAs. J. Gen. Virol. 85:179-184.
80. Wilkinson GW, Kelly C, Sinclair JH, Rickards C. 1998. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. J. Gen. Virol. 79:1233-1245.
81. Wu J, Nandamuri KM. 2004. Inhibition of hepatitis viral replication by siRNA. Expert Opin. Biol. Ther. 4:1649-1659.
82. Yi L, Lin JY, Gao Y, Feng ZJ, Wang DX. 2008. Detection of human cytomegalovirus in the atherosclerotic cerebral arteries in Han population in China. Acta Virol. 52:99-106.
83. Yuan H, et al. 2008. Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am. J. Physiol. Renal Physiol. 295:F605-F617.
84. Yurochko AD, Kowalik TF, Huong SM, Huang ES. 1995. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J. Virol. 69:5391-5400.
85. Zhu H, Shen Y, Shenk T. 1995. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol. 69:7960-7970.
86. Zou H, et al. 2003. Engineered RNase P ribozymes are efficient in cleaving a human cytomegalovirus mRNA in vitro and are effective in inhibiting viral gene expression and growth in human cells. J. Biol. Chem. 278: 37265-37274.